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Abstract
Background: Information on reporting completeness of passive surveillance systems can improve the quality of
and public health response to surveillance data and better inform public health planning. As a result, we
systematically reviewed available literature on reporting completeness of hepatitis A in non-endemic countries.
Methods: We searched Medline, EMBASE and grey literature sources, restricting to studies published in English
between 1997 and 21 May 2015. Primary studies on hepatitis A surveillance and underreporting in non-endemic
countries were included, and assessed for risk of bias. A pooled proportion of reporting completeness was
estimated using a DerSimonian-Laird random-effects model.
Results: Diagnosed hepatitis A cases identified through positive laboratory tests, physician visits, and inpatient
hospital discharges were underreported to public health in all eight included studies. Reporting completeness
ranged from 4 to 97 % (pooled proportion 59 %, 95 % confidence interval = 32 %, 84 %). Substantial heterogeneity
was observed, which may be explained by differences in the referent data sources used to identify diagnosed cases
and in case reporting mechanisms and/or staffing infrastructure. Completeness was improved in settings where
case reporting was automated or where dedicated staff had clear reporting responsibilities.
Conclusions: Future studies that evaluate reporting completeness should describe the context, components, and
operations of the surveillance system being evaluated in order to identify modifiable characteristics that improve
system sensitivity and utility. Additionally, reporting completeness should be assessed across high risk groups to
inform equitable allocation of public health resources and evaluate the effectiveness of targeted interventions.
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Background
Hepatitis A is a disease caused by infection with hepa-
titis A virus (HAV), which is most often transmitted
through the faecal-oral route. In young children, infec-
tion with HAV is typically asymptomatic, while in older
children and adults, infection leads to jaundice in ap-
proximately 70 % of cases [1]. The disease is usually self-
limiting; however, approximately one in four cases are
hospitalized, the proportion increasing with age [2, 3]. In
low-income countries, where the disease is considered
endemic (i.e. the prevalence of anti-HAV antibodies in
the population is ≥ 90 % by age 10), most infections
occur before the age of 5 years, when infections are
asymptomatic and as a result, there are few susceptible
adolescents or adults and few symptomatic infections
[1]. By contrast, in high-income, non-endemic countries,
the prevalence of anti-HAV antibody is very low (<50 %
are immune by age 30) [1] owing to improved sanitary
conditions, along with introduction of an effective vac-
cine in the mid 1990’s. In Canada, reported rates have
declined from 10.6 cases per 100,000 population in 1991
to 0.9 cases per 100,000 population in 2008 [4]. Similar
trends have been observed in the United States (US)
[3, 5]. The risk of infection is low in these countries,
despite a large population of susceptible adults, because
the high standards of living have reduced the effective
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reproduction number below 1, meaning a very low risk of
exposure as there is little circulation of the virus. Despite
this, hepatitis A remains of public health importance. In
2012 and 2013, outbreaks affecting more than 250 individ-
uals were reported across Europe, Canada and the US as a
consequence of travel to endemic regions, as well as im-
portation of contaminated frozen fruit from endemic re-
gions [6–8]. Susceptible populations also remain at high
risk for exposure, including travelers to endemic regions,
men who have sex with men and injection drug users [1].
Hepatitis A cases are typically diagnosed by physicians
on the basis of clinical and epidemiological features, as
well as serological testing to detect immunoglobulin M
(IgM) antibody to HAV [5]. The majority of World
Health Organization (WHO) Member States (71 %, 90/
126) reported having a national surveillance system for
acute hepatitis A infection in a 2012 survey; however,
only 47 % of low-income countries responded to the survey
(compared to 80 % of high-income countries) making it
challenging to understand the true landscape of hepatitis A
surveillance globally [9]. In most high-income countries,
hepatitis A is a notifiable disease. While no universal case
definition exists, in the US, cases reported to public health
are classified as confirmed if they have acute illness with
discrete onset of symptoms, and jaundice or elevated serum
aminotransferase levels, and are laboratory-confirmed (IgM
antibody to HAV (anti-HAV positive)), or they meet the
clinical case definition and have an epidemiologic link with
a person who has laboratory-confirmed hepatitis A [10].
Epidemiological surveillance is conducted passively through
physician and/or laboratory reporting in order to detect
and control outbreaks, as well as to guide and evaluate
public health interventions.
A recognized limitation of these data are their sensitivity
(i.e. data underestimate the total number of cases in the
population). System sensitivity is a function of both case
ascertainment and disease reporting. Under-ascertainment
refers to cases not captured in a surveillance system due to
fact that health care was not sought; this can occur if cases
are asymptomatic, if they do not visit a care provider due
to mild symptoms or other reasons, or if their care pro-
vider does not test for the disease [11, 12]. An estimated
15 % of hepatitis A cases are asymptomatic (although this
proportion can be as high as 70 % in children <6 years
[13]) and 12 % of symptomatic patients are estimated to
not seek care [14]. Underreporting, by contrast, refers to
cases that are diagnosed but are not reported to the appro-
priate public health authorities; this can result from a lack
of knowledge that the disease is notifiable and/or under-
standing of how to report the disease, as well as errors in
the reporting system/mechanism [11, 12].
While not all cases of hepatitis A need to be captured
to achieve maximum control levels (as not all secondary
cases need to be prevented to bring the number of
infections produced on average per case to <1, which is
required for control), a modelling study examining the
impact of reporting delays found that hepatitis A out-
break control would not possible with underreporting
>29 % [15]. As a result, ongoing evaluation and improve-
ment of surveillance systems is necessary to optimize
control efforts. Similarly, completeness of disease ascer-
tainment and reporting should be assessed and corrected
for when estimating the burden of disease from surveil-
lance data, as illustrated by recent infectious disease bur-
den studies in Canada and Europe [16, 17]. Adjustment
is particularly important across key epidemiological
characteristics such as age, sex and risk status, as com-
pleteness of data have been shown to be related to these
characteristics [18, 19]. This information can, in turn,
better inform public health planning, priority setting and
equitable distribution of limited resources.
While the literature on reporting completeness for no-
tifiable diseases has been synthesized overall and for
broad disease groups in the US and the United Kingdom
[12, 20], no such reviews exist for hepatitis A. Disease-
specific data are important as the degree of underreporting
has been shown to vary substantially by disease [12, 20]. As
a result, the objective of this study was to determine the
proportion of diagnosed hepatitis A cases that were re-
ported to public health bodies or agencies in non-endemic
countries. A secondary objective was to synthesize and crit-
ically appraise the methods used to estimate underreporting
to provide recommendations for future studies.
Methods
We followed guidelines from the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
(PRISMA) 2009 statement [21], which is available in
Additional file 1.
Search and study selection
Medline and EMBASE databases were searched on 21st
May 2015. A sensitive strategy comprising two searches
was designed in consultation with two public health
librarians. In search one, mapped subject headings and
keywords for hepatitis A were joined with terms for dis-
ease notification, surveillance and underreporting. In
search two, search terms for hepatitis A were joined with
terms for incidence, prevalence and epidemiology, as
well as travel, non- or low-endemic countries, and country
names. World regions with estimated ‘very low’ endem-
icity, defined as <50 % of the population immune by age
30, were classified as non-endemic [22]. The Medline
search strategy is shown in Table 1. The scope was limited
to non-endemic countries to minimize heterogeneity in
factors known to affect disease surveillance and reporting,
including disease exposure, surveillance and health care
systems, socioeconomic development, and availability of
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treatments [11]. The search was restricted to English arti-
cles published after 1 January 1997 to limit the review to
the time period in which the hepatitis A vaccine was intro-
duced (1996 in Canada; 1995 and 1996 in the US) [4, 23].
Commentaries, editorials, letters, news reports and case
reports were excluded. Reference lists of all studies in-
cluded for full-text review were manually searched for
relevant studies. Additionally, a snowball search was per-
formed for all included articles using the ‘find all related’
function in PubMed to retrieve studies on underreporting
of multiple infectious diseases that did not map ‘hepatitis
A’ as a subject heading or keyword but nonetheless may
have included it as a disease of interest.
Grey literature sources, including websites of the
World Health Organization (WHO), United States
Centers for Disease Control and Prevention (US CDC),
Public Health Agency of Canada (PHAC), European
Centre for Disease Prevention and Control (ECDC) and
EUROHEP.NET were searched using keywords; these
searches were restricted to English and to 2010–2013.
Abstract books from the European Scientific Conference
on Applied Infectious Disease Epidemiology (ESCAIDE),
the International Conference on Emerging Infectious
Diseases (ICEID), and ID Week, held between 2009 and
2013, were also searched.
The primary reviewer (R.D.S.) performed a preliminary
review of article titles and abstracts to exclude irrelevant
studies on non-viral hepatitis, chronic hepatitis, liver
cancer, non-A hepatitis, laboratory detection methods
for hepatitis, and surveillance in non-humans (e.g. ani-
mals, food, water). The remaining article titles and ab-
stracts were independently reviewed by two reviewers
(R.D.S. and K.A.B.); primary studies on hepatitis A sur-
veillance and underreporting in non-endemic countries
were considered relevant for full-text review. Mathemat-
ical modelling papers on hepatitis A were also reviewed
in full-text as a validation measure to ensure all relevant
primary studies were captured in the search, as these
models often account for underreporting. Discordant
views on eligibility were discussed to reach consensus.
Inter-rater reliability between the two reviewers was
assessed using the kappa statistic, where >0.75 indicated
excellent agreement, 0.40–0.75 intermediate to good
agreement, and <0.40 poor agreement [24].
Full-text review was then performed independently by
the two reviewers (R.D.S. and K.A.B.); studies were eli-
gible for inclusion if they assessed underreporting by
comparing hepatitis A disease reports received by public
health with one or more independently retrieved data
source(s) of diagnosed cases as the reference standard
(e.g. IgM anti-HAV positive laboratory test results).
Studies whose aims were to exclusively identify the
source of case reports (i.e. evaluate the proportion of
cases that were reported to public health by physicians,
Table 1 Example Medline search strategy to systematically retrieve literature on hepatitis A underreporting
Search 1a Search Terms
Disease notification, surveillance and
underreporting
Mandatory Reporting/ OR Disease Notification/ OR Contact Tracing/ OR exp Population Surveillance/ OR
Public Health Informatics/ OR exp Data Collection/ OR Disclosure/ OR exp Informatics/ OR underreport$.mp.
OR under-report$.mp. OR (under adj1 report$).mp. OR surveillance.mp. OR reporting.mp. OR ((reported OR
true OR estimate$) adj2 (incidence OR prevalence)).mp. OR undetect$.mp. OR capture-recapture.mp.
AND
Hepatitis A Hepatitis A/ OR Hepatitis A Virus, Human/ OR Hepatitis A Antibodies/ OR “hepatitis a”.mp.
Search 2a Search Terms
Incidence, prevalence and
epidemiology
Incidence/ OR Prevalence/ OR Epidemiology/ OR Statistics & Numerical Data.fs. OR Epidemiology.fs. OR
Epidemiologic Measurements/ OR Statistics as Topic/ OR Data Interpretation, Statistical/ OR incidence.mp.
OR prevalence.mp. OR epidemiolog$.mp.
AND
Hepatitis A Hepatitis A/ OR Hepatitis A Virus, Human/ OR Hepatitis A Antibodies/ OR “hepatitis a”.mp.
AND
Travel, non- or low-endemic
countries
Travel/ OR Travel Medicine/ OR Developed Countries/ OR exp Australia/ OR exp North America/ OR New
Zealand/ OR Andorra/ OR Austria/ OR Belgium/ OR Finland/ OR exp France/ OR exp Germany/ OR Gibraltar/
OR exp Great Britain/ OR Greece/ OR Iceland/ OR Ireland/ OR exp Italy/ OR Liechtenstein/ OR Luxembourg/
OR Monaco/ OR Netherlands/ OR Portugal/ OR San Marino/ OR exp Scandinavia/ OR Spain/ OR Switzerland/
OR Japan/ OR Singapore/ OR Hong Kong/ OR (non-endemic$ OR nonendemic$ OR (non adj1 endemic$)
OR low-endemic$ OR (low adj1 endemic$) OR travel$ OR developed countr$ OR Australia OR North America
OR Canada OR United States OR New Zealand OR Western Europe OR Andorra OR Austria OR Belgium OR
Finland OR France OR Germany OR Gibraltar OR Great Britain OR England OR Scotland OR Ireland OR United
Kingdom OR Wales OR Greece OR Iceland OR Italy OR Liechtenstein OR Luxembourg OR Monaco OR
Netherlands OR Portugal OR San Marino OR Scandinavia OR Spain OR Switzerland OR Cyprus OR Denmark
OR Norway OR Sweden OR Greenland OR Japan OR Singapore OR Hong Kong).mp.
aSearches 1 and 2 were combined using the Boolean operator ‘or’. exp explode – includes all narrower/more specific subheadings in the search, $, allows for
different endings to a word to be searched; mp multi-purpose - searches in the title and abstract as well as the subject heading, adj adjacent, fs floating
subheading – facilitates a broader search (floats over all indexed subject headings)
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laboratories, etc.) were excluded as they did not make
comparisons with a reference standard. Studies also
needed to provide a quantitative measure of underre-
porting or provide data to calculate the degree of under-
reporting for hepatitis A. Reasons for exclusion were
recorded, and as before, discordant views on eligibility
were discussed to reach consensus and inter-rater reli-
ability was assessed.
Data collection
The primary reviewer (R.D.S.) extracted data on the last
name of the first author, year of publication, study set-
ting, the passive surveillance system used to report hepa-
titis A cases, the data source of diagnosed cases used to
measure underreporting, the proportion of diagnosed
cases reported to public health overall and by age, sex
and/or risk status if provided, and the study’s sample size
using a structured data extraction form.
Risk of bias
The methodological quality of included studies was
assessed independently by two reviewers (R.D.S. and
K.A.B.) using Public Health Ontario’s meta-tool for qual-
ity assessment of public health evidence (Table 2) [25].
The validated tool uses a component or checklist ap-
proach to facilitate the assessment of four domains: rele-
vancy, reliability, validity and applicability. The tool
integrates adapted study-design specific critical appraisal
tools and reporting guidelines, such as PRISMA [21],
CONSORT [26] and CASP [27], to assess the study’s val-
idity; however, finding that none of these tools aligned
with the study designs included in this review, a checklist
was created based on two existing reviews of reporting, as
well as the US CDC’s updated guidelines for evaluating
public health surveillance systems [12, 28, 29]. If the study
methodology was inappropriate, biased (e.g. failed to valid-
ate diagnosis in the data source of diagnosed cases), or un-
clear (e.g. failed to describe diagnostic or data linkage
methods), the study was assigned a high risk of bias. If the
methodology was appropriate, clearly defined, and bias-
free, the study was assigned a low risk of bias. If the study
presented findings objectively with justified conclusions,
but the methods were unclear or potentially biased, the
study was rated as moderate risk. Inter-rater reliability
was assessed using the kappa statistic.
Statistical analysis
Reporting completeness was estimated as the number of
diagnosed cases reported to public health divided by the
total number of diagnosed cases ascertained through the
reference standard. If the diagnosis was validated in the
reference standard (e.g. ICD-9 coded hospital discharge
records were reviewed to determine whether hepatitis
A-coded visits met the surveillance case definition), the
corrected denominator was used.
The pooled reporting completeness was derived by
averaging study estimates, weighted by the inverse of
their variance, and transformed using a double arcsine
transformation [30]. The DerSimonian and Laird
random-effects model was used to incorporate between-
study variance and to pool the transformed proportions
[31, 32]. Statistical heterogeneity was assessed by cal-
culating Cochran’s Q statistic with a significance level
of P < 0.10 and the I2 statistic [33], which reflects be-
tween-study heterogeneity. Values of above 75 % were
used to indicate high heterogeneity [33]. All analyses were
performed using MetaXL (http://www.epigear.com). Pub-
lication bias was assessed by visually examining Begg’s
funnel plot and performing Egger’s regression asymmetry




Overall, 1965 studies were retrieved from Medline and
EMBASE, excluding duplicates (Fig. 1). After excluding
354 irrelevant studies in the preliminary review, 1611
studies were screened. Twenty-five studies were consid-
ered eligible for full-text review with good agreement be-
tween reviewers (kappa = 0.60, 95 % confidence interval
(CI) = 0.45, 0.75) (see Additional file 2 for complete ref-
erence list). In total, eight studies were included; six
from the search, one from the reference list of reviewed
full-text articles, and one from the snowball search
[34–41]. There was good agreement between reviewers at
the final screen (kappa = 0.78, 95 % confidence interval
(CI): 0.49, 1.00).
One relevant ECDC project, the ‘Current and Future
Burden of Communicable Diseases in the European
Union and EEA/EFTA countries’ (BCoDE) study, was
identified in the grey literature search. Results from an
unpublished literature scan conducted to aid in the de-
velopment of multiplication factors to correct for under-
ascertainment and underreporting of hepatitis A were
shared by the study lead (written communication, Dr.
Mirjam Kretzschmar). Four articles on underreporting
were cited in this scan, only one of which met our inclu-
sion/exclusion criteria and had already been retrieved
and included in this review [40]. Annual viral hepatitis
surveillance reports published on the US CDC website
were also considered relevant as reports included adjust-
ment for underreporting using a probabilistic model
with factored probabilities of symptoms (I), referral to
care and treatment (II), and rates of reporting to local
and state department (III) [42]. The methodology is pub-
lished and was retrieved in the original, peer-reviewed
literature search [14]. Of the two model inputs for (III),
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the one study that met our inclusion/exclusion
criteria had already been retrieved and included in
this review [36].
Modelling studies
In addition to the 25 primary studies reviewed in full-
text, 24 modelling studies were reviewed (Additional file
2). An additional nine studies were reviewed from the
BCoDE literature scan, for a total of 33 modelling studies
(Additional file 2). No new primary studies on underre-
porting of hepatitis A were identified.
Characteristics of included primary studies
Studies were published between 1998 and 2011, and
conducted between 1995 and 2007 (Table 3). The major-
ity (6/8) were from the US [34–37, 39, 41]; one study
was from England [40] and another from New Zealand
[38]. Hepatitis A was notifiable, meaning that it was leg-
islated to be reported to public health, for all study set-
tings during the study time periods. In most settings,
there was a mandatory dual (physician and laboratory)
reporting mechanism. Aside from one study that exam-
ined the proportion of positive test results identified
Table 2 Adapted meta-tool for quality assessment of public health evidence (Meta QAT) from Public Health Ontario [25]
Item Criteria Assessment
Validity a) Are findings presented objectively?
• Clear rationale and justification
• Findings presented and discussed within appropriate context
• Similar to existing literature and if not, reasons explained





b) Are the authors conclusions justified?
• Transparency
• Results consistent with those described in discussion





Reliability a) Is the research methodology clearly described?
• Study population and surveillance system described
• Can identify the research design





b) Is methodology appropriate for the scope of research?a
• Comparison with an appropriate reference standard (i.e. a data source other than notification data)?
o Is the sensitivity of the reference standard described? Are cases verified?
o Is the population base for notifications and supplementary data sources drawn from same catchment area?
o Is there an adequate description of case ascertainment?
o Are cases ascertained for the same time period in both datasets?
• Are the data sources to be compared clearly identified and described/referenced?
• What case definition is used? Is the same definition applied to all data sources?
• Are the methods for linkage described?
o Were the identifiers unique and available?
o How complete was the link? (% linked)
o How accurate was the link? (i.e. were individuals linked who were not supposed to be or vice versa)
o Were duplicate cases identified and removed?
• How precise are results? (confidence interval width)
• Were any statistical measures of agreement used (did authors express level of agreement using a statistic)?
• For capture-recapture methods:
o If dependency between data sources is suspected, are ≥3 or more data sources used, along with log linear modelling





c) Is the research methodology free from bias?
• Are there major sources of bias?





d) Are ethics procedures described?






e) Can I be confident about findings?
• Were sources of information quality assessed?





Applicability Can results be applied within the scope of public health?
• Do the results of the study apply to the issue under consideration (i.e. are surveillance systems and supplementary data





aReliability, section b was revised from the original tool based on studies from Doyle et al. (2002) and Pillaye and Clarke (2003), as well as the US CDC’s updated
guidelines for evaluating public health surveillance systems [12, 28, 29]
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within a managed care organization’s reporting system
and another study that examined electronic medical re-
cords from a group practice [34, 36], all studies were
population-based, meaning that cases could emerge
from anywhere in the population and through any
healthcare setting. Only one study measured underre-
porting in an outbreak context [40].
Risk of bias
There was good agreement between the two reviewers
for bias assessment (kappa = 0.79, 95 % confidence inter-
val (CI): 0.41, 1.00). Overall, two studies were assessed
to have a low risk of bias, four studies a moderate risk,
and two a high risk (Table 4). One of the most common
study limitations was a failure to verify the diagnosis in
the reference standard. For example, only two studies
that used ICD-9 coded hospital discharge data to ascer-
tain cases of hepatitis A verified the diagnosis though
medical chart review [35, 41]. Study authors found that
this process identified several false positives, which had
they not been detected, would have led to an artificially
low completeness of reporting estimate. For studies that
linked diagnostic and public health data to estimate
underreporting, the methods for matching and accuracy
of the match were poorly described in most studies.
Additionally, several studies did not report the case defini-
tions or criteria used to ascertain cases and whether the
definitions were consistent across data sources [34, 40];
although, it should be noted that a national surveillance
case definition for hepatitis A did not exist in England at
the time of the study conducted by Matin et al. [40] Re-
portable disease surveillance data varies by system design
and implementation; despite this, most studies provided
only a cursory description of the various data sources and
population coverage of those sources and did not include
relevant contextual information important to interpreting
reporting completeness estimates.
Data synthesis
In all included studies, hepatitis A reporting was found
to be incomplete. The proportion of hepatitis A cases re-
ported to public health ranged from 4 to 97 % (pooled
proportion = 59 %, 95 % CI = 32 %, 84 %) (Table 3 and
Fig. 2). High heterogeneity was observed (Q = 1117.30,
P < 0.001; I2 = 99 %). Reporting completeness estimates
were not stratified by age, sex or risk status in any of
the included studies (data not shown).
The majority of studies (7/8) linked public health noti-
fication data with an independently retrieved data source
of diagnosed cases to measure underreporting (Table 3)
[34–39, 41]. The most commonly used reference stand-
ard was positive IgM anti-HAV test results from labora-
tories [34, 37–39]; two studies used inpatient hospital
discharge data validated through medical record review
to assess underreporting [35, 41], while another used
electronic medical records [36]. Only one study used
capture-recapture methods applied to two hepatitis A
outbreaks to measure underreporting [40]. The hetero-
geneity in reporting completeness may be explained in
part by the differing standards used. In a post-hoc
Fig. 1 Flow chart of search strategy results and selection of papers
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Table 3 Characteristics of eight included studies published between January 1997 and May 2015
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subgroup analysis, studies which assessed completeness
by comparing public health data with laboratory testing
data found that a higher proportion of cases were re-
ported to public health (pooled proportion = 77 %, 95 %
CI = 43 %, 99 %); however, significant residual hetero-
geneity remained (Fig. 3).
With the exception of one study [37], no studies re-
ported which anti-HAV IgM test was used, the sensitiv-
ity and specificity of the test, and whether there were
any changes to laboratory testing procedures over the
study time period, making it difficult to assess whether
the heterogeneity could be explained by differences in
testing practices/methods. The variation could also be
explained by differences in how (or the mechanism by
which) cases were reported to public health (e.g. auto-
mated versus manual reporting methods, electronic ver-
sus paper, staff resource level, etc.) and legislation across
and within study settings. For example, higher estimates
of reporting completeness were observed in the two
studies with automated laboratory reporting (97 and 88 %)
[34, 39] relative to the other two studies that relied on
manual reporting methods (74 and 65 %) [37, 38]. The lat-
ter also cited specific challenges with reporting including
poor information exchange with private laboratories [37],
and lack of routine reporting by selected laboratories [38].
If data from these four studies were pooled, cases detected
in automated reporting systems would have had 3.92
times the odds of being reported to public health com-
pared to cases detected in manual reporting systems.
Other studies that similarly relied on manual, passive
reporting but in different settings (by infection control
practitioners [39] and primary care providers [36]) also
found lower proportions of complete reporting (4 and
25 %). In addition to between study variation, Sickbert-
Bennett et al. (2011) noted heterogeneity in reporting
mechanisms within one health region, finding higher
reporting completeness in hospitals with dedicated staff
(i.e. public health epidemiologists or infection control
practitioners) responsible for disease reporting [41].
There was no evidence of publication bias based on
funnel plot symmetry between the proportion of reporting
completeness and the standard error of the proportion
(Fig. 4) or from Egger’s test (P = 0.977).
Discussion
The body of literature on the sensitivity of passive sur-
veillance systems to capture diagnosed hepatitis A cases
reveals that hepatitis A is underreported in non-endemic
countries. The majority of studies were conducted in the
US; despite this, there was substantial variability in
reporting completeness (range: 4 to 97 %). Previous



















Yes Yes Yes Yes Yes Yes Yes Yes
Validity Presented
objectively
Unclear Unclear Unclear Unclear Yes Yes Yes Yes
Conclusions
justified
Yes Yes Yes Yes Yes Yes Yes Yes
Reliability Clear methods Yes Yes Yes Yes Unclear Unclear Yes Unclear
Appropriate
methods
Unclear Yes Yes Yes Unclear Unclear Yes Yes
Free from bias No Yes Unclear No Unclear Unclear No Unclear
Ethics
described
Unclear Unclear Unclear Unclear No Unclear Yes Yes
Confident in
findings
Unclear Yes Unclear Unclear No No Unclear No
Applicability Applicable Unclear Yes Yes Unclear Unclear Yes Yes Yes
Overall Risk High Low Moderate Moderate High Moderate Low Moderate
Fig. 2 Pooled proportion of hepatitis A reporting completeness to
public health in eight studies. CI confidence interval
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systematic reviews on completeness of disease notifica-
tion for all reportable diseases in the US and UK simi-
larly found variability in estimates depending on the
disease, ranging from 9 to 99 % and 3 to 95 %, respect-
ively [12, 20]. These studies, however, covered all notifi-
able diseases and found that reporting completeness was
strongly correlated to the disease itself and not to study
characteristics such as study location, time period, study
design, and study size. Consequently, heterogeneity in
estimates was attributed to the wide number of diseases
being evaluated.
We found that the disparate reference standards (data
sources of diagnosed cases) used by the studies in this
review contributed in part to the observed variation in
reporting completeness; however, substantial heterogen-
eity remained among studies which evaluated reporting
completeness through comparison with laboratory test-
ing data. Reporting completeness was highest where
laboratory reporting to public health was automated
relative to manual reporting methods and in settings
where dedicated staff were responsible for disease
reporting. These findings provide specific direction as to
how surveillance systems can be improved to minimize
underreporting.
Differences in important contextual factors, namely
disease incidence and vaccination policy, in US states
may have also influenced laboratory and physician report-
ing completeness. Unlike New Zealand and England vac-
cine recommendations which target high risk groups, HAV
vaccination recommendations in the US have employed a
phased approach, starting first with high risk groups, then
moving in 1999 to target 17 states with reported rates
above the national average [23] and in 2006 to all children
over 1 year of age [5]. California and Colorado were both
included in the targeted approach in 1999; it is possible
that the improved reporting completeness relative to the
studies from other settings was a result of heightened
vigilance of reporting in this specific context [34, 35].
Other contributing factors to the observed heterogen-
eity could include varying study time periods, quality,
sample size and/or legislative requirements for notifica-
tion; although, no clear trend was observed across these
factors. There may be additional features unique to each
surveillance system that influence reporting complete-
ness (e.g. regular auditing or other quality improvement
activities, etc.). These features are challenging to eluci-
date, however, as many studies only provided a cursory
description of their surveillance system, despite recom-
mendations from the US CDC’s Guidelines Working
Group for Evaluating Public Health Surveillance Systems
to report on the context, operations, and system com-
ponents, including the level of integration with other
systems, when conducting an evaluation [23]. Efforts
Fig. 3 Pooled hepatitis A reporting completeness in studies with
laboratory testing data as the reference standard. CI confidence interval
Fig. 4 Funnel plot for assessing publication bias of hepatitis A reporting completeness in non-endemic countries
Savage et al. BMC Infectious Diseases  (2016) 16:281 Page 9 of 12
to contact study authors to obtain this information
were either unsuccessful or impeded by recall issues.
As this information is vital to identify those unique
features that improve or impede system sensitivity,
and can be used to improve the quality of systems
everywhere, we recommend that future evaluation
studies prioritize the inclusion of this information.
Methodological limitations identified in included studies
provide further insight into how future studies evaluating
the sensitivity of surveillance systems can be improved
(recommendations summarized in Table 5). Several stud-
ies did not describe how cases were diagnosed in the refer-
ence standard and many did not take steps to validate the
diagnosis in any way. For studies using positive IgM anti-
HAV laboratory test results as the reference standard, false
positive test results or repeat testing may have overesti-
mated the denominator and underestimated the propor-
tion of cases reported to public health, although, the
specificity of IgM anti-HAV testing has been shown to be
≥99 % [43]. By contrast, lack of clinical information in an
electronic medical record may have resulted in false nega-
tives, which would have overestimated reporting com-
pleteness [36]. Application of a different case definition in
the reference standard from that used for surveillance
may have also led to disease misclassification. For ex-
ample, using positive IgM anti-HAV laboratory test results
alone to ascertain cases in laboratory data without consid-
eration of the presence of clinically compatible symptoms,
a component of the surveillance case definition, may have
underestimated reporting completeness. Similarly, studies
have demonstrated that using only ICD-9 hepatitis A
discharge diagnosis codes, without verification by med-
ical chart review, overestimates cases as defined by the
surveillance case definition [35, 41]. Lastly, methods
used to match records in the diagnostic and public
health datasets, such as deterministic or probabilistic
linkage, and the accuracy of the match was often not
described; record linkage errors may have similarly
underestimated reporting completeness or resulted in
other errors. Given that surveillance reports are typic-
ally brief in nature, it is unclear whether these concerns
reflect true methodological issues, or issues related to
reporting quality.
Strengths of this review include a comprehensive
search strategy which included two key scientific litera-
ture databases and relevant grey literature sources iden-
tified by experts in hepatitis A and public health
surveillance. Search methods were validated using mod-
elling studies and communication with public health
professionals at two core knowledge-generating public
health organizations. Additionally, adaptation of the
critical appraisal tool better facilitated the identifica-
tion of fundamental issues affecting each included
study’s internal validity.
The scope of the study was restricted to focus on
underreporting and not under-ascertainment as report-
ing practices are amenable to quality improvement,
while issues related to under-ascertainment are less so,
particularly when cases are asymptomatic, mild or have
self-limiting infections that do not require medical care.
Nonetheless, under-ascertainment remains an important
contributor to the sensitivity of passive surveillance sys-
tems and can have substantial effects on disease control
and prevention. Improving health literacy (knowledge of
the severity or duration of an illness, and when to seek
care), and removing administrative, financial and cul-
tural barriers to healthcare may improve case ascertain-
ment [19]. From a methodological perspective, the
degree to which under-ascertainment occurs for a par-
ticular disease in a community can be estimated through
the use of a wide range of active case finding methods,
including serial serosurveys, as described by Gibbons et
al. (2014) [19]. These estimates can then, in turn, be
used to calibrate surveillance data.
Conclusions
Given that complete and timely reporting of notifiable
diseases is important to prevent outbreaks and person-
to-person transmission, efforts should be undertaken to
improve and evaluate surveillance on an ongoing basis.
Automating case reporting to public health and/or pro-
viding dedicated staffing infrastructure with clear staff
reporting responsibilities can improve reporting com-
pleteness. To identify additional modifiable features of
surveillance systems and provide specific direction on
how to improve system sensitivity and utility, future
studies should describe the context, operations, and
components of their system when conducting an evalu-
ation, as well as critically reflect on how these features
contributed to low or high sensitivity. Lastly, priority
should be given to improving the quality of risk factor data
recorded in surveillance systems to enable estimation of
Table 5 Summary of recommendations for future studies
evaluating completeness of surveillance by linking public health
surveillance data with a reference standard
1. Report on the context, operations, and system components of the
public health surveillance system being evaluated, including the level
of integration with other systems.
2. Provide the surveillance case definition (if available), and describe
how cases were diagnosed in the reference standard. If possible,
apply the surveillance case definition to the reference standard to
avoid misclassification in ascertaining cases.
3. Validate the diagnosis of cases in the reference standard if possible,
particularly if using inpatient hospital discharges or electronic medical
records as reference standards.
4. Describe methods used to match or link records in the diagnostic
and public health datasets, such as deterministic or probabilistic
linkage, and the accuracy of the match.
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reporting completeness across high risk groups; these data
are essential to examine equity issues, inform allocation of
public health resources including control measures, and
evaluate the effectiveness of public health interventions
including vaccine recommendations.
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